Trial · NCT01186003
Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
NCT01186003, Not applicable, Completed, University of Colorado, Denver; results first posted 2021-12-07
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy. Trials, record NCT01186003. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01186003
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Effectiveness of Adding Subcutaneous Long-Acting Detemir to Insulin Drip Therapy Compared With Standard Insulin Drip Therapy
- NCT number
- NCT01186003
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 30 participants, actual
- Lead sponsor
- University of Colorado, Denver
- Conditions
- Diabetes
- Interventions
- Detemir
- First posted
- 2010-08-20
- Last updated
- 2021-12-07
- Results first posted
- 2021-12-07
- Limitations and caveats
We have no information regarding whether many of the outcome measure were collected or analyzed. The PI has retired, and CU Clinical Research Administration has contacted the study team and PI on numerous occasions to try and obtain the data, but have not been able to do so. Therefore, several outcome measures cannot be reported.
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl) | within 48 hours of discontinuation | Number of participants exhibiting rebound hyperglycemia (blood glucose levels over 180 mg/dl) |
| Secondary | Reduction in Duration of Insulin Drip Therapy and Reduction in Total and Average Per Hour Insulin Drip Dose | within one week of insulin drip therapy | |
| Secondary | Reduction in ICU Length of Stay | within two weeks of hospitalization | |
| Secondary | Equal or Improved Diabetes Control | within two weeks of hospitalization | |
| Secondary | Reduction in Time to Get Back to Control of Glycemia (140-180 mg/dl) if Rebound Hyperglycemia Occurs | within one week post insulin drip |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl) | within 48 hours of discontinuation | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Reduction in Duration of Insulin Drip Therapy and Reduction in Total and Average Per Hour Insulin Drip Dose | within one week of insulin drip therapy | We have no information regarding whether this outcome measure was collected or analyzed. The PI has retired, and CU Clinical Research Administration has contacted the study team and PI on numerous occasions to try and obtain the data, but have not been able to do so. Therefore, this outcome measure cannot be reported. | ||
| SECONDARY | Reduction in ICU Length of Stay | within two weeks of hospitalization | We have no information regarding whether this outcome measure was collected or analyzed. The PI has retired, and CU Clinical Research Administration has contacted the study team and PI on numerous occasions to try and obtain the data, but have not been able to do so. Therefore, this outcome measure cannot be reported. | ||
| SECONDARY | Equal or Improved Diabetes Control | within two weeks of hospitalization | We have no information regarding whether this outcome measure was collected or analyzed. The PI has retired, and CU Clinical Research Administration has contacted the study team and PI on numerous occasions to try and obtain the data, but have not been able to do so. Therefore, this outcome measure cannot be reported. | ||
| SECONDARY | Reduction in Time to Get Back to Control of Glycemia (140-180 mg/dl) if Rebound Hyperglycemia Occurs | within one week post insulin drip | We have no information regarding whether this outcome measure was collected or analyzed. The PI has retired, and CU Clinical Research Administration has contacted the study team and PI on numerous occasions to try and obtain the data, but have not been able to do so. Therefore, this outcome measure cannot be reported. |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl) | Standard Insulin Drip Therapy | 14 | Participants | ||
| Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl) | Insulin Drip and Detemir | 3 | Participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Standard Insulin Drip Therapy | 14 | |
| Overall Study | STARTED | Insulin Drip and Detemir | 16 | |
| Overall Study | COMPLETED | Standard Insulin Drip Therapy | 14 | |
| Overall Study | COMPLETED | Insulin Drip and Detemir | 16 | |
| Overall Study | NOT COMPLETED | Standard Insulin Drip Therapy | 0 | |
| Overall Study | NOT COMPLETED | Insulin Drip and Detemir | 0 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Standard Insulin Drip Therapy | 0 | 14 |
| Total, all-cause mortality | Insulin Drip and Detemir | 0 | 16 |
| Total, other adverse events | Standard Insulin Drip Therapy | 0 | 14 |
| Total, other adverse events | Insulin Drip and Detemir | 0 | 16 |
| Total, serious adverse events | Standard Insulin Drip Therapy | 0 | 14 |
| Total, serious adverse events | Insulin Drip and Detemir | 0 | 16 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons3
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Standard Insulin Drip Therapy vs Insulin Drip and Detemir: Reduction in Rebound Hyperglycemia (Blood Glucose Levels Over 180 mg/dl) | Trial comparisons |
| Standard Insulin Drip Therapy vs Insulin Drip and Detemir: deaths from any cause | Trial comparisons |
| Standard Insulin Drip Therapy vs Insulin Drip and Detemir: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01186003
GET https://conductscience.org/api/trials/v1/NCT01186003/registered